<DOC>
	<DOCNO>NCT01474876</DOCNO>
	<brief_summary>This 12-month postmarketing observational study ( PMOS ) prospective , single-arm , multicenter , multi-country study , follow-up visit 3 , 6 , 9 , 12 month initial baseline visit . The study conduct determine long-term effectiveness treatment adalimumab routine clinical use participant Ankylosing Spondylitis ( AS ) Psoriatic Arthritis ( PsA ) Central Eastern European Countries .</brief_summary>
	<brief_title>Multi-country Post-Marketing Observational Study Maintenance Effectiveness Adalimumab ( Humira® ) Patients With Ankylosing Spondylitis Psoriatic Arthritis</brief_title>
	<detailed_description>Additional study objective evaluate AS PsA regard extra-articular manifestation ( EAMs ) , functional status , use concomitant nonsteroidal anti-inflammatory medication , work productivity impairment . In addition , Ankylosing Spondylitis Disease Activity Score ( ASDAS ) , new disease activity index AS , measure parallel standard Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) score assess effectiveness adalimumab treat axial symptom .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients enrol Postmarketing observational study PMOS fulfill criterion : 1 . Adult patient diagnosis Ankylosing Spondylitis ( AS ) Psoriatic Arthritis ( PsA ) . 2 . Eligible adalimumab therapy accord local product label prescription/reimbursement guideline . 3 . Have prescribe adalimumab within maximum one ( 1 ) month prior study enrolment . 4 . Have negative result Tuberculosis ( TB ) screen test TB prophylaxis per local guideline . 5 . Are willing provide Authorization investigator use and/or disclose personal and/or health data , provide Informed Consent request Local Regulations , entry study . Patients fulfil exclusion criterion eligible Postmarketing study ( PMOS ) : 1 . Meet contraindication treatment adalimumab outline late version local Summary Product Characteristics ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Post-marketing observational study ( PMOS ) Protocol</keyword>
	<keyword>Effectiveness Adalimumab ( HUMIRA® )</keyword>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>